1. Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767-80. https://doi.org/10.18632/oncotarget.8194 PMid:27004404 PMCid:PMC5130043.
2. Breitenstein MK, Simon G, Ryu E, Armasu SM, Weinshilboum RM, Wang L, et al. Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics. Stud Health Technol Inform. 2015;210:914-8. https://doi.org/10.3233/978-1-61499-512-8-914 PMID:25991289.
3. El-Arabey AA. Update on off label use of metformin for obesity. Prim Care Diabetes. 2018;12(3):284-5. https://doi.org/10.1016/j.pcd.2018.02.004 PMid:29525383.
4. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-5. https://doi.org/10.1136/bmj.38415.708634.F7 PMid:15849206 PMCid:PMC558205.
5. Tseng CH. Metformin and lung cancer risk in patients with type 2 diabetes mellitus. Oncotarget. 2017;8(25):41132-42. https://doi.org/10.18632/oncotarget.17066 PMid:28456789 PMCid:PMC5522244.